1 mL BAC
10 units
resulting U-100 draw
- Concentration
- 15 mg/mL
- BAC added
- 1 mL
BlendNot ApprovedMixedVery Low confidenceSourced
Tesamorelin / Ipamorelin blend
A growth-hormone-axis blend not represented by the authorised tesamorelin product or by the intravenous ipamorelin clinical programme.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
A community Tesamorelin / Ipamorelin blend shown as total mass per subcutaneous injection from a 15 mg vial (10 mg Tesa + 5 mg Ipa, 2:1). The name implies 1:1 and separate-component reports run about 8:1, so ratios conflict; community reports only, not validated.
Reported maximum quantity
Tesamorelin-led titration (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.Reported quantities by phase
Select a point for its calculation examples- Lower (1 mg Tesa)1.5 mg total15 mg blend = 10 mg Tesamorelin + 5 mg Ipamorelin (2:1); 1.5 mg total delivers ~1 mg Tesamorelin plus ~0.5 mg Ipamorelin per injection.
- Higher (2 mg Tesa)3 mg total+1 mg Tesamorelin3 mg total delivers ~2 mg Tesamorelin plus ~1 mg Ipamorelin. Separate-component reports instead pair 1-2 mg Tesamorelin with only 200-250 mcg Ipamorelin (~8:1), which this fixed 2:1 vial and the name's 1:1 label do not reproduce.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 1.5 mg total reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
2 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw20 U
20-30 U reference band
2 mL BAC
20 units
resulting U-100 draw
- Concentration
- 7.5 mg/mL
- BAC added
- 2 mL
Shown in the diagram. Closest of these examples to 25 units.
3 mL BAC
30 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 3 mL
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Formulation MathFixed-ratio blendNo validated frequency
Arithmetic check for a fixed 5 mg plus 5 mg blend
Every draw from a true 1:1 blend delivers equal milligram quantities of tesamorelin and ipamorelin
The referenced third-party page proposes unequal 2:1 component quantities, which cannot be obtained from a homogeneous 1:1 vial. No compatible combined schedule is therefore displayed.
View sourceCommunity GuideSubcutaneous in reportsOnce daily during the reported phases
online research community separate-component self-experiments
The best-documented phases used 1 mg tesamorelin plus 250 mcg ipamorelin and 2 mg plus 500 mcg once daily in the morning for three weeks
These unequal ratios came from separately measured components and cannot be reproduced from a homogeneous 1:1 blend. Other channel examples use different ratios and timing; raw/growing-pains-ghrh-gh-igf-insulin.md:31-37.
View sourceCommunity GuideSubcutaneous in reportsOnce daily; Ipamorelin sometimes split
authenticated research-forum (Peppys) Tesamorelin and Ipamorelin reports
The best-documented forum logs run Tesamorelin 1-2 mg subcutaneously with Ipamorelin about 200-250 mcg, most often once daily fasted in the morning or with Tesamorelin at bedtime and Ipamorelin split; several note that 1 mg Tesamorelin alone can already push IGF-1 to the top of range and that Ipamorelin roughly amplifies the effect, so some run as little as 100-200 mcg of each. These are separately measured components at roughly an 8:1 Tesamorelin-to-Ipamorelin ratio, not a homogeneous 1:1 blend
Forum provenance from an authenticated archive with usernames and post numbers omitted. The reported ratios of about 5-10:1 Tesamorelin to Ipamorelin cannot be reproduced from a 1:1 vial; quantities conflict and are titrated against IGF-1 testing. These are community provenance, not controlled human dose finding, and the growth-hormone-axis components are kept separate rather than interconverted.
View sourceEvidence summary
A growth-hormone-axis blend not represented by the authorised tesamorelin product or by the intravenous ipamorelin clinical programme.
Protocol basis
The components have evidence in different formulations, routes and populations. No source establishes that combining them produces an equivalent or acceptable protocol.
Community provenance (Peppys)
Although the archive's cautious top-line flag understates it, the forum in fact carries a curated Tesamorelin and Ipamorelin protocol and several detailed logs. Those reports run Tesamorelin around 1-2 mg subcutaneously with Ipamorelin near 200-250 mcg, most often once daily fasted in the morning or with Tesamorelin at bedtime and Ipamorelin split, and titrate against IGF-1 testing; some observe that 1 mg of Tesamorelin alone already tops the IGF-1 range and that Ipamorelin amplifies the effect, so they run lower amounts of each. Critically, these are separately measured components at roughly an 8:1 Tesamorelin-to-Ipamorelin ratio, which the blend's display name (implying 1:1) does not reflect and a homogeneous vial cannot reproduce. Reported quantities conflict, usernames and post numbers are omitted, and the figures are community provenance; the planner above shows only the arithmetic of a fixed-ratio blend and does not validate it.
What remains uncertain
Combined exposure, endocrine effects, formulation compatibility, long-term safety and clinical benefit are unknown.
Warnings and contraindications
No adequate controlled human study of the combined formulation was identified.
Authorised tesamorelin evidence does not validate adding ipamorelin.
Both components affect the growth-hormone axis and require clinical monitoring in studied settings.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.